In this prospective study, we compared ddPCR data of hotspot mutations for four therapeutically relevant genes (BRAF, EGFR, KRAS, PIK3CA) from three different patient-matched sample types (FFPE, CTC-derived DNA and plasma-ctDNA) from early- stage NSCLC patients before surgery. This evidence concerns the gene KRAS and non-small cell lung carcinoma.